Aspirin makes up the first-line treatment for patients with coronary artery disease. Nevertheless, some recent studies have suggested that the response to regular use of aspirin is not uniform in patients with chronic coronary artery disease, and still little studied in the setting of acute coronary syndromes. However, the lack of standardization and variability of platelet aggregation tests used to measure response to aspirin did not allow a definitive conclusion on the subject. The main objective of this analysis is to evaluate the correlation between two methods of platelet aggregation widespread in medical practice, whole blood aggregometry and Verify-Now. This will included 50 patients with acute coronary syndromes without ST-segment elevation on previous use of AAS for analyzes of platelet aggregation within 48 hours of onset and three months later. The present analysis will be linked to the study "inadequate response to aspirin in coronary disease: comparison between acute and chronic phases.
News published in Agência FAPESP Newsletter about the scholarship: